Saturday, September 19, 2020 1:30:59 PM
A Real big climb to make and strong competition as it's a drug that has not passed Safety Phase 1 status. Cancer Cell auxopathy drugs were tried (I owned one) in Trials, but immunotherapy is the standard now.
This is why Aviptadil, as a repurposed drug, has moved so fast so far. They moved directly to Phase 2 Trials and will be allowed for Phase 3 when signals are there. (same as another *dil)
Most cancers were 90%+ fatal, especially if they are Metastatic. Now maybe 50% have lived to require no further treatments even with Metastatic complications.
Remdesivir has a 12% benefit and Colonoquin is harmful and ineffective yet were pumped and still used.
The need for a COVID solution or combination of treatments that actually are effective is NOW, with really NONE commonly available. IMO..GLTA...
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM